Theravance Biopharma Antibiotics

Theravance Biopharma is a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines. The company utilizes its proprietary multivalent drug design platform to create small molecule therapies with improved efficacy and safety profiles, particularly in respiratory and neurological health. While the company historically developed and commercialized the antibiotic Vibativ (telavancin) for serious bacterial infections through its antibiotics division, this asset was divested to Cumberland Pharmaceuticals in 2018. Currently, the company's portfolio includes Yupelri (revefenacin) for COPD and a significant royalty interest in GSK's Trelegy Ellipta. Its lead clinical program, ampreloxetine, is in Phase 3 development for symptomatic neurogenic orthostatic hypotension. Theravance Biopharma is headquartered in the Cayman Islands with principal operating facilities in South San Francisco and Dublin.